Posters

      A Highly Sensitive Method For The Quantification Of Key Oxysterols In Plasma Using Liquid Chromatography With High Resolution Mass Spectrometry

      Della Gatta, S.; Arndt, D.; Bentley, M.
      Conference date
      Jun 16, 2013
      Conference name
      HPLC 2013 – THE 39TH INTERNATIONAL SYMPOSIUM ON HIGH-PERFORMANCE-LIQUID-PHASE SEPARATIONS AND RELATED TECHNIQUES
      Link to more information
      Summary

      Oxysterols are oxygenated derivatives of cholesterol, which have been demonstrated to be present at increased levels in the plasma of patients with cardiovascular disease and are considered as possible biomarkers for disease onset. High resolving power and mass accuracy afforded by mass spectrometers based on Orbitrap™ technology provides unique advantages for the screening and simultaneous quantitation of oxysterols in complex biological matrices, which are normally present in trace amounts. However, the chromatographic separation remains crucial since many oxysterols are structural isomers. A sensitive method for the quantification of nine key oxysterols, namely 7-α-hydroxycholesterol, 7-β-hydroxycholesterol, 7-ketocholesterol, 24-hydroxycholesterol, 25-hydroxycholesterol, 27-hydroxycholesterol, 5α, 6α- epoxycholestanol, 5β, 6β-epoxycholestanol and 6α-hydroxy-5α-cholestane, using high resolution mass spectrometry is described. The method is applicable to both human and mouse plasma. Liquid/liquid extraction with dichloromethane and methanol was applied to mouse plasma samples without any additional derivatization step, and an alkaline hydrolysis was employed to cleave sterol-fatty acid conjugates. The oxysterols were separated by reversed phase liquid chromatography and detected using atmospheric pressure chemical ionization in positive ion mode on a Gexactive™ mass spectrometer operated in full scan mode with a resolving power of 70.000 FWHM. Target analytes were confirmed using accurate mass and were quantified using peak area ratios, with individual deuterium-labeled internal standards present for each target compound. The method showed analytical accuracy based on a standard addition recovery test within +/-10% and excellent linearity across the calibration range from 5 to 5000 ng/ml (r2>0.9948). Precision within 15% was achieved for the whole range of analytes. Compared to traditional LC-MS/MS approaches, this method demonstrated accuracy and sensitivity without any additional need for analyte derivatization, and the acquisition of full scan data maintained the opportunity for retrospective data evaluation to investigate related analyte species, which were not considered at the point of the analysis.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.